Patients who achieved PR harbored the following aberrations: FGFR2 Y376C (n = 1), FGFR3 A393E (n = 1), and FGFR3-TACC3 fusions (n = 2)....The 6-month PFS was 0% for patients harboring FGFR amplifications, 6% (90% CI, 1% to 30%) for SNVs, and 56% (90% CI, 31% to 100%) for FGFR fusions (Fig 4D). Two of the 4 patients who achieved a PR had a PFS > 9.5 months; their primary tumors were intrahepatic cholangiocarcinoma and urothelial carcinoma of the renal pelvis.